Clinical TrialAug 6, 2026, 08:05 AM
Annexon's Tanruprubart Shows Early Positive GBS Clinical Trial Results
AI Summary
Annexon announced early positive results from its open-label FORWARD study for tanruprubart in Guillain-Barré syndrome (GBS) patients. The first ten U.S. and European patients showed rapid, clinically meaningful improvement in strength and reduced disability within days of treatment. These outcomes reinforce previous Phase 3 and real-world evidence, positioning tanruprubart as a potential first approved targeted therapy for GBS. A Biologics License Application (BLA) submission is targeted for Q4 2026, and the drug is currently under review by the EMA.
Key Highlights
- All 10 GBS patients showed rapid, clinically meaningful improvement in muscle strength within four days.
- Four bedbound patients walked with or without assistance between day two and eight.
- One ventilated patient came off the ventilator within four days of treatment.
- Five other patients demonstrated marked gains in function within 48 hours.
- Tanruprubart was generally well-tolerated, consistent with Phase 3 results.
- BLA submission for tanruprubart is targeted for Q4 2026.
- Tanruprubart's Marketing Authorisation Application is under review by the EMA.
- GBS represents a >$20 billion annual U.S. healthcare burden with no approved targeted therapies.
Price Impact
More from ANNX